JUN 01, 2017 7:08 AM PDT

Drug Could Give Months Back to Pancreatic Cancer Patients

WRITTEN BY: Xuan Pham

Pancreatic cancer is a ruthless killer - about three-quarters of patients don’t make it past the one-year mark from diagnosis. But a new drug could give some precious months back to patients fighting this disease.

In a Phase 2 randomized clinical trial led by researchers at the Fred Hutchinson Cancer Research Center, an experimental drug called PEGPH20 seemed to make pancreatic cancer more vulnerable to chemotherapy treatments.

Image: Mayo Foundation

The drug targets molecules known as hyaluronic acid (HA), which have a high affinity for water. In pancreatic cancer, HA molecules enable the tumor to build up high internal pressure, which forces nearby blood vessels to shut down. This mechanism prevents cancer-fighting drugs to reach the heart of the tumor, contributing to the disease’s dismal prognosis.

But HA molecules are broken down in presence of PEGPH20, which researchers hypothesized would make pancreatic tumors vulnerable to chemotherapy. Indeed, mouse studies with PEGPH20 supported this hypothesis, as mice treated with the drug had tumor shrinkage and increased survival time.

The current trial involved 234 late-stage pancreatic cancer patients who were randomized to receive chemotherapy in conjunction with PEGPH20 or chemotherapy alone. When researchers analyzed survival time in this large group, they reported minor increases of several weeks of progression-free survival.

"If this was all the potential that this strategy represented, I wouldn't pursue this [research further]," said Sunil Hingorani, the lead investigator of the trial. "That's not enough for me."

But remarkable results happened when the team separated cancers based on HA levels. Indeed, patients whose tumors were high in HA responded more to PEGPH20. This resulted in more significant tumor shrinkage, and an increase in four months of progression-free survival. And four months is quite impressive considering the speed at which pancreatic cancer kills.

The results are promising enough to warrant proceeding to Phase 3. "We still haven't fully proven anything yet, strictly speaking, but I think [this strategy] is very rational," said Hingorani. "Let me put it this way: I think it would be irresponsible not to finish the global Phase 3 trial as the most rigorous test of this hypothesis. I think we're obligated now to answer the question."

Because the drug seems to work best in tumors high in HA, only patients whose tumors meet this criteria will be eligible for Phase 3 testing. If results of Phase 3 are as promising, the drug could be up for FDA approval in the future.

"Patients get one shot on goal, if that, with this cancer," he said. "No cancer is more daunting than pancreas cancer."

Additional source: Fred Hutchinson Cancer Research Center via EurekAlert!

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAY 16, 2021
Cancer
Can you guess which drug is both antiviral and immunotherapeutic?
MAY 16, 2021
Can you guess which drug is both antiviral and immunotherapeutic?
Hepatitis B virus (HBV) is the most common cause of liver cancer in the world, resulting in approximately 880,000 deaths ...
MAY 19, 2021
Cancer
How does environmental quality affect prostate cancer aggressiveness?
MAY 19, 2021
How does environmental quality affect prostate cancer aggressiveness?
A study from researchers at the University of Illinois Chicago investigates the link between environmental quality and p ...
JUN 16, 2021
Cell & Molecular Biology
A Potential Way to Prevent Metastatic Cancer
JUN 16, 2021
A Potential Way to Prevent Metastatic Cancer
Metastatic cancer is the deadliest, and it can happen years after cancer has been treated to the point of remission. Met ...
JUN 16, 2021
Cancer
New drug attacks pancreatic tumors with mutant KRAS addiction
JUN 16, 2021
New drug attacks pancreatic tumors with mutant KRAS addiction
Pancreatic cancer is notoriously difficult to detect in early stages, which is why it is associated with a low survival ...
JUL 23, 2021
Cancer
Repurposed Antibiotics Show Promise Against Skin Cancer
JUL 23, 2021
Repurposed Antibiotics Show Promise Against Skin Cancer
In experiments with mice, researchers from the Netherlands have found that some antibiotics may be effective in tre ...
SEP 18, 2021
Genetics & Genomics
Cancer Genes Might Aim for the Immune System, Not Growth Promotion
SEP 18, 2021
Cancer Genes Might Aim for the Immune System, Not Growth Promotion
The DNA in our cells can accumulate damage over may years. Environmental influences like UV light or cigarette smoke may ...
Loading Comments...